Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.94 - $4.61 $3,298 - $7,837
1,700 Added 2.68%
65,100 $250,000
Q1 2024

May 15, 2024

BUY
$1.99 - $5.64 $106,863 - $302,868
53,700 Added 553.61%
63,400 $140,000
Q4 2023

Feb 14, 2024

SELL
$3.07 - $10.25 $37,761 - $126,075
-12,300 Reduced 55.91%
9,700 $52,000
Q3 2023

Nov 14, 2023

SELL
$10.52 - $20.68 $29,456 - $57,904
-2,800 Reduced 11.29%
22,000 $239,000
Q2 2023

Aug 14, 2023

BUY
$17.18 - $23.76 $352,190 - $487,080
20,500 Added 476.74%
24,800 $542,000
Q1 2023

May 15, 2023

SELL
$18.25 - $30.26 $113,150 - $187,612
-6,200 Reduced 59.05%
4,300 $79,000
Q4 2022

Feb 14, 2023

BUY
$12.36 - $26.41 $129,780 - $277,305
10,500 New
10,500 $271,000

Others Institutions Holding OM

About Outset Medical, Inc.


  • Ticker OM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 48,007,300
  • Market Cap $27.4M
  • Description
  • Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was ...
More about OM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.